Paper Details

  1. Home
  2. Paper Details

Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial.

Author: , CrowleyConstance A, HealdPeter, MartinAnn G, MehlmauerMarilyn, ReichSteven D, YocumRichard C

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study evaluated the safety and efficacy of topical bexarotene gel 1% in patients with refractory or persistent early-stage cutaneous T-cell lymphoma. The study found that topical bexarotene gel was generally well tolerated and demonstrated substantial efficacy, with an overall response rate of 54%.
Paper Details　
Original Abstract of the Article :
OBJECTIVES: We sought to determine the safety and efficacy of topical bexarotene (Targretin; Ligand Pharmaceuticals, La Jolla, Calif) gel 1% in patients with refractory or persistent early-stage cutaneous T-cell lymphoma. METHODS: We conducted a multinational, open-label, phase III study of 50 pati...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/14576658

データ提供：米国国立医学図書館（NLM）

Topical Bexarotene: A New Approach to Cutaneous T-Cell Lymphoma

Cutaneous T-cell lymphoma (CTCL) is a type of cancer that affects the skin. This study evaluates the efficacy and safety of topical bexarotene (Targretin) gel 1% in patients with refractory or persistent early-stage CTCL. The researchers conducted a phase III clinical trial involving 50 patients to assess the treatment's effectiveness and identify any potential side effects.

Topical Bexarotene: A Promising Treatment Option for CTCL

The study revealed that topical bexarotene gel demonstrated significant efficacy in patients with refractory or persistent early-stage CTCL. The overall response rates were substantial, indicating that this treatment could offer a viable option for patients with this challenging condition. The study also found that the treatment was generally well tolerated, with most adverse events being mild to moderate. This positive finding suggests that topical bexarotene could be a valuable tool for managing CTCL.

Navigating Treatment Options for Cutaneous T-Cell Lymphoma

The results of this study offer hope for patients with CTCL, providing a potentially effective and well-tolerated treatment option. However, it is important to remember that treatment decisions should be made in consultation with healthcare providers, considering individual patient characteristics and the potential for side effects. This study underscores the importance of ongoing research and development to find new and innovative therapies for CTCL, ultimately improving the lives of patients with this condition.

Dr.Camel's Conclusion

Topical bexarotene is like a refreshing oasis in the desert for CTCL patients. The researchers have discovered a potentially effective and well-tolerated treatment option, bringing hope to those seeking relief from this challenging condition. This study is a testament to the dedication of researchers who are tirelessly working to improve the lives of patients with CTCL. Just as a camel can navigate harsh desert environments, researchers continue to navigate the complexities of cancer research, seeking new and innovative treatments that offer hope for a healthier future.

Date :
  1. Date Completed 2004-08-30
  2. Date Revised 2019-07-09
Further Info :

Pubmed ID

14576658

DOI: Digital Object Identifier

S0190962203014750

Related Literature

Article Analysis
・Effects of bexarotene topical
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.